Answers are grounded in this paper and cite their sources.
Background Female infertility often requires coordinated diagnostic, surgical, and assisted reproductive strategies. Robotic-assisted surgery (RAS) may facilitate selected fertility-preserving procedures, while artificial intelligence (AI) is increasingly applied to reproductive imaging, embryo assessment, ovarian stimulation, prognosis, and clinical decision support. The clinical evidence for both technologies is uneven, and direct AI integration into robotic infertility surgery remains early. Main body This critical review evaluates current evidence for RAS in myomectomy, tubal reanastomosis, endometriosis surgery, adhesiolysis, ovarian surgery, and selected reconstructive procedures, alongside clinically relevant AI applications in assisted reproduction and reproductive imaging. RAS may offer technical advantages in complex cases through enhanced visualization, instrument articulation, ergonomics, and suturing, but superiority over expert conventional laparoscopy for cumulative live birth, time to pregnancy, ovarian reserve preservation, and cost-effectiveness remains insufficiently established. AI can improve standardization and prediction, but many models remain retrospective, internally validated, incompletely calibrated, or insufficiently tested for clinical utility. We propose a clinical maturity framework that distinguishes current surgeon-controlled RAS from research-stage AI support and speculative autonomous surgery. The most plausible near-term AI-RAS integration is clinician-supervised support for preoperative imaging, surgical difficulty prediction, intraoperative video analytics, robotic skill assessment, postoperative fertility prognosis, and sequencing of surgery and assisted reproductive technology. Conclusion AI and RAS may become complementary components of female infertility care, but routine integrated use requires multicenter prospective validation, standardized infertility-specific outcomes, transparent AI reporting, patient-centered evaluation, regulatory oversight, and assessment of cost and equity.
No takes yet. Share an insight, caveat, or question.
Motamed et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: